Johnson and Johnson Stock Analysis: Solid Uptrend with Bullish Analyst Sentiment

# Johnson & Johnson (JNJ) Stock Analysis: Strong Momentum at $240+ with Bullish Analyst Targets | Market Update 2024 Dive into the latest **Johnson & Johnson stock analysis** as JNJ shares trade above $240, showcasing impressive momentum in the pharmaceutical and healthcare sector. This comprehensive episode examines JNJ's recent performance, including its $579.75 billion market cap and solid Q1 earnings of $2.46 EPS on $24.28 billion revenue. Discover why 27 Wall Street analysts maintain a **"moderate buy" consensus** with an average price target of $234.87. We break down recent upgrades from major firms including **Citigroup's $250 target**, **Morgan Stanley's $262 overweight rating**, and **Argus's boost to $240**. Key highlights include: - JNJ's upward trend with 50-day MA at $228.36 and 200-day MA at $204.19 - Attractive 47% dividend payout ratio for income investors - Strong institutional ownership at 69.55% - PE ratio of 21.77 indicating reasonable valuation - 52-week range analysis: $141.50 to $251.71 Perfect for investors seeking **pharmaceutical stock insights**, **dividend investing strategies**, and **healthcare sector analysis**. Whether you're a long-term investor or active trader, this episode provides actionable market intelligence on one of healthcare's blue-chip leaders. Subscribe for regular **stock market updates** and **investment analysis**. A Quiet Please Studios production. #StockMarket #JNJ #JohnsonAndJohnson #Investing #MarketAnalysis #DividendStocks #Healthcare #Pharmaceuticals For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.